Journal Scans
Dasatinib Treatment of Chronic Phase Chronic Myeloid Leukemia: Analysis of Responses According to Preexisting BCR-ABL Mutations
Dasatinib in Imatinib-Resistant, BCR-ABL–Mutated CML
MC Muller, JE Cortes, D-W Kim, BJ Druker, P Erben, R Pasquini, S Branford, TP Hughes, JP Radich, L Ploughman, J Mukhopadhyay, A Hochhaus
20090824
2009 Sept 24
Blood
Dasatinib Treatment of Chronic Phase Chronic Myeloid Leukemia: Analysis of Responses According to Preexisting BCR-ABL Mutations
Blood. 2009 Sept 24;[Epub Ahead of Print], MC Muller, JE Cortes, D-W Kim, BJ Druker, P Erben, R Pasquini, S Branford, TP Hughes, JP Radich, L Ploughman, J Mukhopadhyay, A Hochhaus
TAKE-HOME MESSAGE
Abstract
Abstract
Dasatinib is a BCR-ABL inhibitor with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Imatinib failure is commonly caused by BCR-ABL mutations. Here, dasatinib efficacy was analyzed in patients recruited to phase II/III trials with chronic myeloid leukemia in chronic phase with or without BCR-ABL mutations after prior imatinib. Among 1,043 patients who underwent mutational assessment, 39% had a BCR-ABL mutation prior to dasatinib therapy, including 48% of 805 patients with...
